Our center has also conducted a clinical study of CD19 CAR-T for the treatment of systemic lupus erythematosus (NCT06056921), which has been administered to two patients, both of whom have demonstrated improvement and a favorable safety profile. Here, CD19 is linked to systemic lupus erythematosus.